These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21411801)

  • 21. Evaluation of a modified vancomycin nomogram for obese adults.
    Batchelder N; Lutheran CF; Frens J
    Eur J Clin Pharmacol; 2020 Mar; 76(3):403-408. PubMed ID: 31834422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testing the predictive ability of the "spinal cord injury equation" in estimating vancomycin clearance.
    Lee JP; Wang YJ
    Am J Health Syst Pharm; 2013 Apr; 70(8):669-74. PubMed ID: 23552044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
    Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
    Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients.
    Leader WG; Tsubaki T; Chandler MH
    Am J Hosp Pharm; 1994 Sep; 51(17):2125-30. PubMed ID: 7985687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.
    Natale S; Bradley J; Nguyen WH; Tran T; Ny P; La K; Vivian E; Le J
    Pharmacotherapy; 2017 Mar; 37(3):361-378. PubMed ID: 28079262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters.
    Murphy JE; Gillespie DE; Bateman CV
    Am J Health Syst Pharm; 2006 Dec; 63(23):2365-70. PubMed ID: 17106010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of phenytoin loading doses in overweight patients using actual versus adjusted body weight.
    Keats K; Powell R; Rocker J; Waller J; Coppiano LS
    Epilepsy Behav; 2022 Sep; 134():108833. PubMed ID: 35839643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
    Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of methods to estimate glomerular filtration rate versus actual drug clearance in patients with chronic spinal cord injury.
    Lee JP; Dang AT
    Spinal Cord; 2011 Dec; 49(12):1158-63. PubMed ID: 21788951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vancomycin volume of distribution estimation in adults with class III obesity.
    Dunn RD; Crass RL; Hong J; Pai MP; Krop LC
    Am J Health Syst Pharm; 2019 Dec; 76(24):2013-2018. PubMed ID: 31630155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients.
    Flechner SM; Kolbeinsson ME; Tam J; Lum B
    Transplantation; 1989 May; 47(5):806-10. PubMed ID: 2655218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive performance of a vancomycin-aminoglycoside population model.
    Beringer PM; Wong-Beringer A; Rho JP
    Ann Pharmacother; 1998 Feb; 32(2):176-81. PubMed ID: 9496400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of a vancomycin dosage regimen developed for obese patients.
    Reynolds DC; Waite LH; Alexander DP; DeRyke CA
    Am J Health Syst Pharm; 2012 Jun; 69(11):944-50. PubMed ID: 22610026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating creatinine clearance in morbidity obese patients.
    Dionne RE; Bauer LA; Gibson GA; Griffen WO; Blouin RA
    Am J Hosp Pharm; 1981 Jun; 38(6):841-4. PubMed ID: 7246555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.
    Healy MF; Speroni KG; Eugenio KR; Murphy PM
    Ann Pharmacother; 2012 Apr; 46(4):477-83. PubMed ID: 22474135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of a divided-load intravenous vancomycin dosing strategy for critically ill patients.
    Denetclaw TH; Dowling TC; Steinke D
    Ann Pharmacother; 2013 Dec; 47(12):1611-7. PubMed ID: 24259632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage.
    Matzke GR; Kovarik JM; Rybak MJ; Boike SC
    Clin Pharm; 1985; 4(3):311-5. PubMed ID: 4006395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.
    Hong J; Krop LC; Johns T; Pai MP
    Pharmacotherapy; 2015 May; 35(5):455-63. PubMed ID: 26011138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug Development.
    Wang J; Kumar SS; Sherwin CM; Ward R; Baer G; Burckart GJ; Wang Y; Yao LP
    Clin Pharmacol Ther; 2019 Jun; 105(6):1462-1470. PubMed ID: 30565653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.